STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #3679 by analyst upside · 2026-06-27
NVS
Novartis AG
Healthcare · Market Cap $297B · P/E 22.2x
ANALYST PRICE TARGET
-1.0%
implied upside to consensus target
Current Price $155.41
Consensus Target $153.87
Bull Target $180.0
Bear Target $123.0
Analysts Covering 10
ANALYST CONSENSUS — BUY
Strong Buy
2
Buy
2
Hold
5
Sell
1
52-Week Low $112.34
52-Week High $170.46
YTD Return +15.6%
FUNDAMENTALS
Market Cap $297B
P/E Ratio (TTM) 22.2x
Forward P/E 15.6x
EPS (TTM) $6.99
PEG Ratio 4.15
Dividend Yield 3.05%
Revenue (TTM) $56.6B
Profit Margin 23.9%
52-WEEK RANGE
52-Week Low $112.34
52-Week High $170.46
Current Price $155.41
Bear Target $123.0
Bull Target $180.0
● Now $155.41 ● Target $153.87
TRADING DATA
Avg Volume 1.7M
YTD Return +15.6%
Analyst Count 10
Consensus Buy
Upside to Target -1.0%
Last Updated 2026-06-27

ANALYST SUMMARY

Novartis AG (NVS) is currently trading at $155.41 with a Wall Street consensus price target of $153.87, which is 1.0% below the current price over the next 12 months. 10 analysts currently cover NVS, with a consensus rating of Buy — 40% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $180.0, while the most cautious has a target of $123.0.

NVS operates in the Healthcare sector with a market capitalisation of $297B. The stock is up 15.6% year-to-date and is currently trading near the upper end of its 52-week range of $112.34 – $170.46.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for NVS, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Morgan Stanley — Reiterated
Overweight → Overweight 2026-03-26 Building track record
Barclays ↑ Upgrade
Underweight → Equal-Weight 2026-01-06 Building track record
JP Morgan ↑ Upgrade
Neutral → Overweight 2025-12-08 43% win rate (7 calls)
Goldman Sachs ↓ Downgrade
Neutral → Sell 2025-09-12 Building track record
UBS ↓ Downgrade
Buy → Neutral 2025-02-13 33% win rate (6 calls)
Erste Group ↓ Downgrade
Buy → Hold 2024-11-19 Building track record
BMO Capital — Reiterated
Market Perform → Market Perform 2024-10-30 Building track record
B of A Securities ↓ Downgrade
Buy → Neutral 2024-09-11 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
out of 100
Coverage depth
0/30
Consensus clarity
0/30
Vote unanimity
0/25
Rating stability
0/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call — not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →